Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGM-101 in Rectal Cancer Surgery
NCT04642924Phase 3Unknown
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2019
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 3, open-label trial of sgm-101 in rectal cancer (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Resection status. Status: unknown.
02
Drugs
sgm-101
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04642924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04642924.